Vitamins E and C are safe across a broad range of intakes

American Journal of Clinical Nutrition

Volumn 81, Issue 4, 2005, Pages 736-745

  Hathcock, John N ^a   Azzi, Angela ^b   Blumberg, Jeffrey ^c   Bray, Tammy ^d   Dickinson, Annette ^a   Frei, Balz ^d   Jialal, Ishwarlal ^e   Johnston, Carol S ^f   Kelly, Frank J ^g   Kraemer, Klaus ^h   Packer, Lester ⁱ   Parthasarathy, Sampath ^j   Sies, Helmut ^k   Traber, Maret G ^d  

^a International and Scientific Affairs   (United States)

^b UNIVERSITY OF BERN   (Switzerland)

^c TUFTS UNIVERSITY   (United States)

^d OREGON STATE UNIVERSITY   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f ARIZONA STATE UNIVERSITY   (United States)

^g KING'S COLLEGE LONDON   (United Kingdom)

^h BASF SE   (Germany)

ⁱ UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^j LOUISIANA STATE UNIVERSITY   (United States)

^k HEINRICH HEINE UNIVERSITY   (Germany)

more..

Author keywords

Ascorbic acid; Clinical trials; Risk assessment; Safety; Tocopherol; Vitamin C; Vitamin E; tocopherol

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; ESTROGEN; NICOTINIC ACID; PLACEBO; RAMIPRIL; SIMVASTATIN; WARFARIN;

ALZHEIMER DISEASE; BLEEDING; CANCER PREVENTION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG EFFECT; DRUG INHIBITION; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERURICOSURIA; IRON ABSORPTION; IRON METABOLISM; KIDNEY FAILURE; META ANALYSIS; NEPHROLITHIASIS; REVIEW; SIDE EFFECT; SYSTEMATIC REVIEW; VITAMIN INTAKE; VITAMIN SUPPLEMENTATION; CONTROLLED CLINICAL TRIAL; FEMALE; HEALTH CARE POLICY; MALE; RANDOMIZED CONTROLLED TRIAL;

ANTIOXIDANTS; ASCORBIC ACID; FEMALE; HUMANS; MALE; NUTRITION POLICY; RANDOMIZED CONTROLLED TRIALS; VITAMIN E;

EID: 17844398242     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcn/81.4.736     Document Type: Review

References (95)

1. Jialal I, Devaraj S. Antioxidants and atherosclerosis: don't throw out the baby with the bath water. Circulation 2003;107:926-8.
2. Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study Group. The effect of vitamin E and beta-carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994;330:1029-35.
3. Leppala JM, Virtamo J, Fogelholm R, et al. Controlled trial of alpha-tocopherol and beta-carotene supplements on stroke incidence and mortality in male smokers. Arterioscler Thromb Vasc Biol 2000;20:230-5.
4. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 1999;354:447-55.
5. Heart Outcomes Prevention Evaluation Study Investigators. Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med 2000;342:154-60.
6. Chylack LT Jr, Brown NP, Bron A, et al. The Roche European American Cataract Trial (REACT): a randomized clinical trial to investigate the efficacy of an oral antioxidant micronutrient mixture to slow progression of age-related cataract. Ophthalmic Epidemiol 2002;9:49-80.
7. Lonn E, Yusuf S, Dzavik V, et al. Effects of rampiril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 2001; 103:919-25.
8. Hodis HN, Mack WJ, LaBree L, et al. Alpha-tocopherol supplementation in healthy individuals reduces low-density lipoprotein but not atherosclerosis: the vitamin E atherosclerosis prevention study (VEAPS). Circulation 2002;106:1453-9.
9. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360: 23-33.
10. Council for Responsible Nutrition. Supplement usage patterns of U.S. adults: consumer survey conducted by Ipsos-Reid. Washington, DC: Council for Responsible Nutrition, 2001.
11. NBJ's annual overview of the nutrition industry VI. Nutr Bus J 2001; 6(5/6): 1-7, 17-8.
12. Food and Nutrition Board, Institute of Medicine. Dietary reference intakes for vitamin C, vitamin E, selenium, and carotenoids. A report of the Panel on Dietary Antioxidants and Related Compounds, Subcommittees on Upper Reference Levels of Nutrients and Interpretation and Uses of Dietary Reference Intakes, and the Standing Committee on the Scientific Evaluation of Dietary Reference Intakes. Washington, DC: National Academy Press, 2000.
13. Scientific Committee on Food. Opinion of the Scientific Committee on Food on the tolerable upper intake level of vitamin E. European Commission, SCF/CS/NUT/UPPERLEV/31 Final, 23 April 2003. Internet: http://europa.eu.int/ comm/food/fs/sc/scf/outl95_en.pdf (accessed 2 June 2003).
14. Scientific Panel on Dietetic Products, Nutrition and Allergies. Opinion of the Scientific Panel on Dietetic Products, Nutrition and Allergies related to the tolerable upper intake level of vitamin C (L-ascorbic acid, its calcium, potassium and sodium salts and L-ascorbyl-6-palmitate). Eur Food Safety Authority J 2004;59:1-21.
15. Expert Group on Vitamins and Minerals (convened and supported by the Food Standards Agency of the United Kingdom). Safe upper levels for vitamins and minerals, May 2003. Internet: http://www.foodstandards-.gov.uk/multimedia/pdfs/ vitmin2003.pdf (accessed 2 June 2003).
16. Bendich A, Machlin LJ. Safety of oral intake of vitamin E. Am J Clin Nutr 1988;48:612-9.
17. Kappus H, Diplock AT. Tolerance and safety of vitamin E: a toxicological position report. Free Radic Biol Med 1992;13:55-74.
18. Miller ER III, Pastor-Barriuso R, Dalai D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005;142:37-46.
19. Eidelman RS, Hollar D, Hebert PR, Lamas GA, Hennekens CH. Randomized trials of vitamin E in the treatment and prevention of cardiovascular disease. Arch Intern Med 2004;164:1552-6.
20. Shekelle PG, Morton SC, Jungvig LK, et al. Effect of supplemental vitamin E for the prevention and treatment of cardiovascular disease. J Gen Intern Med 2004;19:380-9.
21. Vivekananthan DP, Penn MS, Sapp SK, Hsu A, Topol EJ. Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet 2003;361:2017-23.
22. Gillilan RE, Mondell B, Warbasse JR. Quantitative evaluation of vitamin E in the treatment of angina pectoris. Am Heart J 1977;93:444-9.
23. Meydani SN, Meydani M, Blumberg JB, et al. Assessment of the safety of supplementation with different amounts of vitamin E in healthy older adults. Am J Clin Nutr 1998;63:311-8.
24. Stephens NG, Parsons A, Schofield PM, et al. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996;347:781-6.
25. Anderson TW, Reid DB. A double-blind trial of vitamin E in angina pectoris. Am J Clin Nutr 1974;27:1174-8.
26. Farrell PM, Bieri JG. Megavitamin E supplementation in man. Am J Clin Nutr 1975;28:1381-6.
27. Inagaki Y, Kinoshita MO, Nakamura Y, Masuda YA. Double-blind controlled of the efficacy of all-rac-alpha tocopherylnicotinate in patients with vascular disease. In: DeDuve C, Hayashi O, eds. Tocopherol, oxygen and biomembranes. New York: Elsevier-North Holland, 1978: 338-9.
28. Stampfer MJ, Willett W, Castelli WP, et al. Effect of vitamin E on lipids. Am J Clin Pathol 1983;79:714-6.
29. Bierenbaum ML, Noonan FJ, Machlin LJ, et al. The effect of supplemental vitamin E on serum parameters in diabetics, postcoronary and normal subjects. Nutr Res Int 1985;31:1171-80.
30. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 1997;336:1216-22.
31. Parkinson Study Group. Mortality in DATATOP: a multicenter trial in early Parkinson's disease. Ann Neurol 1998;43:318-25.
32. Boaz M, Smetana S, Weinstein T, et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000;356:1213-8.
33. Salonen JT, Nyyssonen K, Salonen R, et al. Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) study: a randomized trial of the effect of vitamins E and C on 3-year progression of carotid atherosclerosis. J Intern Med 2000;248:377-86.
34. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001;119:1417-36.
35. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-92.
36. de Gaetano G, Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet 2001;357:89-95.
37. Taylor HR, Tikellis G, Robman LD, et al. Vitamin E supplementation and macular degeneration: randomised controlled trial. BMJ 2002; 325:11.
38. Salonen RM, Nyyssonen K, Kaikkonen J, et al. Six-year effect of combined vitamin C and E supplementation on atherosclerotic progression: The Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) Study. Circulation 2003;107:947-53.
39. Cheung MC, Xue-Qiao Z, Chait A, et al. Antioxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL. Arterioscler Thromb Vasc Biol 2001;21:1320-6.
40. Corrigan JJ Jr. The effect of vitamin E on warfarin-induced vitamin K deficiency. Ann N Y Acad Sci 1982;393:361-8.
41. Dowd P, Zheng ZB. On the mechanism of the anticlotting action of vitamin E quinone. Proc Natl Acad Sci U S A 1995;92:8171-5.
42. Kim JM, White RH. Effect of vitamin E on the anticoagulant response to warfarin. Am J Cardiol 1996;77:545-6.
43. McDermott JH. Antioxidant nutrients : current dietary recommendations and research update. J Am Pharm Assoc 2000;40:785-99.
44. Booth SL, Golly I, Sacheck JM, et al. Effect of vitamin E supplementation on vitamin K status in adults with normal coagulation status. Am J Clin Nutr 2004;80:143-8.
45. Freedman JE, Farhat JH, Loscalzo J, Keaney JF Jr. Alpha-tocopherol inhibits aggregation of human platelets by a protein kinase C-dependent mechanism. Circulation 1996;94:2434-40.
46. Garewal HS, Diplock AT. How safe are antioxidant vitamins? Drug Safety 1995;13:8-14.
47. Levine M, Rumsey SC, Daruwala R, et al. Criteria and recommendations for vitamin C intake. JAMA 1999;281:1415-23.
48. Stein HB, Hasan A, Fox IH. Ascorbic acid-induced uricosuria. Ann Intern Med 1976;84:385-8.
49. Levine M, Corny-Cantilena C, Wang Y, et al. Vitamin C pharmacokinetics in healthy volunteers: evidence for a recommended dietary allowance. Proc Natl Acad Sci U S A 1996;93:3704-9.
50. Creagan ET, Moertel CG, O'Fallon JR, et al. Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. N Engl J Med 1979;301:687-90.
51. Ludvigsson J, Hansson IO, Stendahi O. The effect of large doses of vitamin C on leukocyte function and some laboratory parameters. Int J Vitam Nutr Res 1979;49:160-5.
52. Knodell RG, Tate MA, Akl BF, et al. Vitamin C prophylaxis for post-transfusion hepatitis: lack of effect in a controlled trial. Am J Clin Nutr 1981;34:20-3.
53. Tsao CS, Salimi SL. Effect of large intake of ascorbic acid on urinary and plasma oxalic acid levels. Int J Vitam Nutr Res 1984;54:245-9.
54. Moertei CG, Fleming TR, Creagan ET, et al. High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. N Engl J Med 1985;312:137-41.
55. Ono K. Secondary hyperoxalemia caused by vitamin C supplementation in regular hemodialysis patients. Clin Nephrol 1986;26:239-43.
56. Omaye ST, Skala JH, Jacob RA. Plasma ascorbic acid in adult males: effects of depletion and supplementation. Am J Clin Nutr 1986;44: 257-64.
57. Brigden ML, Edgell D, McPherson M, et al. High incidence of significant urinary ascorbic acid concentrations in a West Coast population-implications for routine urinalysis. Clin Chem 1991;38:426-31.
58. Johnston CS, Retrum KR, Srilakshmi JC. Antihistamine effects and complications of supplemental vitamin C. J Am Diet Assoc 1992;92: 988-9.
59. Hunt JR, Gallagher SK, Johnston LK. Effect of ascorbic acid on apparent iron absorption by women with low iron stores. Am J Clin Nutr 1994; 59:1381-5.
60. Wandzilak TR, D'Andre SD, Davis PA, et al. Effect of high dose vitamin C on urinary oxalate levels. J Urol 1994;151:834-7.
61. Fuller CJ, Grundy SM, Norkus EP, et al. Effect of acerbate supplementation on low density lipoprotein oxidation in smokers. Atherosclerosis 1996;119:139-50.
62. Jacob RA, Kutnink MA, Csallany AS, et al. Vitamin C nutriture has little short-term effect on vitamin E concentrations in healthy women. J Nutr 1996;126:2268-77.
63. Podmore ID, Griffiths HR, Herbert KE, et al. Vitamin C exhibits pro-oxidant properties. Nature 1998;392:559 (letter).
64. Rehman A, Collis CS, Yang M, et al. The effects of iron and vitamin C co-supplementation on oxidative damage to DNA in healthy volunteers. Biochem Biophys Res Commun 1998;246:293-8.
65. Fuller CJ, May MA, Martin KJ. The effect of vitamin E and vitamin C supplementation on LDL oxidizability and neutrophil respiratory burst in young smokers. J Am Coll Nutr 2000;19:361-9.
66. Vojdani A, Bazargan M, Vojdani E, et al. New evidence for antioxidant properties of vitamin C. Cancer Detect Prev 2000;24:508-23.
67. 2-induced DNA damage in human lymphocytes. Br J Nutr 2000;84:195-202.
68. Porkkala-Saratao E, Salonen JT, Nyyssonen K, et al. Long-term effects of vitamin E, vitamin C, and combined supplementation on urinary 7-hydro-8-oxo-2′-deoxyguanosine, serum cholesterol oxidation products, and oxidation resistance of lipids in nondepleted men. Arterioscler Thromb Vasc Biol 2000;20:2087-93.
69. Levine M, Wang Y, Padayatty SJ, et al. A new recommended dietary allowance of vitamin C for healthy young women. Proc Natl Acad Sci U S A 2001;98:9842-6.
70. Johnston CS, Cox SK. Plasma-saturating intakes of vitamin C confer maximal antioxidant protection to plasma. J Am Coll Nutr 2001;20: 623-7.
71. Hajjar IM, George V, Sasse EA et al. A randomized, double-blind, controlled trial of vitamin C in the management of hypertension and lipids. Am J Ther 2002;9:289-93.
72. Huang HY, Appel LJ, Croft DK, et al. Effects of vitamin C and vitamin E on in vivo lipid peroxidation: results of a randomized controlled trial. Am J Clin Nutr 2002;76:549-55.
73. Aghdassi E, Wendland BE, Steinhart AH, et al. Antioxidant vitamin supplementation in Crohn's disease decreases oxidative stress: a randomized controlled trial. Am J Gastroenterol 2003;98:348-53.
74. Lenton KJ, Sane AT, Therriault H, et al. Vitamin C augments lymphocyte glutathione in subjects with ascorbate deficiency. Am J Clin Nutr 2003;77:189-95.
75. Bendich A, Cohen M. Ascorbic acid safety: analysis of factors affecting iron absorption. Toxicol Lett 1990;51:189-201.
76. Cook JD, Watson SS, Simpson KM, et al. The effect of high ascorbic acid supplementation on body iron stores. Blood 1984;64:721-6.
77. Maxwell SRJ. Antioxidant vitamin supplements: update of their potential benefits and possible risks. Drug Safety 1999;4:253-66.
78. Rivers JM. Safety of high-level vitamin C ingestion. Int J Vitam Nutr Res Suppl 1989;30:95-102.
79. Diplock AT. Safety of antioxidant vitamins and beta carotene. Am J Clin Nutr 1995;62(suppl):1510S-6S.
80. Balcke P. Schmidt P, Zazgornik J, et al. Ascorbic acid aggravates secondary hyperoxalemia in patients on chronic hemodialysis. Ann Intern Med 1984;101:344-5.
81. 6and the risk of kidney stones in men. J Urol 1996;155:1847-51.
82. Hathcock JN. Vitamins and minerals: efficacy and safety. Am J Clin Nutr 1997;66:427-37.
83. Hoffer A. Ascorbic acid and kidney stones. Can Med Assoc J 1985;132: 320 (letter).
84. Mitch WE, Johnson MW, Kirshenbaum JM, Lopez RE. Effect of large oral doses of ascorbic acid on uric acid excretion by normal subjects. Clin Pharmacol 1981;29:318-21.
85. Schmidt KH, Hagmaier V, Hornig DH, et al. Urinary oxalate excretion after large intakes of ascorbic acid in man. Am J Clin Nutr 1981;34:305-11.
86. Fituri N, Allawi N, Bentley M, Costello J. Urinary and plasma oxalate during ingestion of pure ascorbic acid: a re-evaluation. Eur Urol 1983; 9:312-5.
87. Johnston CS. Biomarkers for establishing a tolerable upper intake level for vitamin C. Nutr Rev 1999;57:71-7.
88. Frei B, Traber M. The new dietary reference intakes for vitamin C and E. Redox Rep 2001;6:5-9.
89. Lee D-H, Folsom AR, Halliwell B, Jacobs DR Jr. Does supplemental vitamin C increase cardiovascular disease risk in women with diabetes? Am J Clin Nutr 2004;80:1194-200.
90. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience. Eur Heart J 1999;20:725-41.
91. Waters DD, Alderman EL, Hsia J, et al. Effect of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women. JAMA 2002;288: 2432-40.
92. Hathcock JN. Vitamins and hormone therapy for coronary atherosclerosis. JAMA 2003;289:982 (letter).
93. Bjelakovic G, Nikolova D, Simonetti RG, Gluud C. Antioxidant supplements for prevention of gastrointestinal cancers: a systematic review and meta-analysis. Lancet 2004;364:1219-28.
94. Egger M, Smith GD, Phillips AN. Meta-analysis: principles and procedures. Br Med J 1997;315:1533-7.
95. Food and Nutrition Board. Dietary reference intakes: a risk assessment model for establishing upper intake levels for nutrients. Washington, DC: National Academy Press, 1998.